Instant International
Written by: Ou Jingluo
2021-01-13 12:43
Last update date: 2021-01-13 12:45
The Butantan Institute in Brazil announced on January 12 that the new coronavirus (SARS-CoV-2) vaccine developed by Kexing Biotechnology is only 50.4% effective, which is far lower than the initial expectations of the outside world.
There have been criticisms that the data released by the authorities are confusing, and the multiple postponements of the release also make it suspect that the main reason is that the efficacy of the vaccine is not as high as expected.
The picture shows the press conference of the Brazilian Institute of Butantan on January 7. The authorities originally planned to announce the clinical test report of Kexing vaccine, but temporarily announced the postponement.
(Reuters)
Brazil's Butantan Institute and Coxing cooperated in the third phase of clinical trials in Brazil.
Since the number of people in the experiment exceeds 12,000, which is the highest among all participating countries, it is considered to best reflect the effectiveness of the vaccine.
The Butantan Institute announced on the 12th that the effective rate of Kexing vaccine is 50.4%.
This is far from the 78% announced by the Butantan Institute earlier. The Butantan Institute explained that it did not include data on mild and asymptomatic patients at the time. After adding the figures, it was only 50.4% "overall effective rate." "Although the vaccine is 100% effective in preventing severe illness.
Indonesia announced on the 11th that the effective rate of Kexing's vaccine was 65.3%, but only 1,600 people participated in the test; Turkey announced that the effective rate of the vaccine was 91% and only 1,300 people participated in the test.
The effective rate of 50.4% just passed the threshold of the World Health Organization (WHO), which is also the lowest effective rate among all new coronavirus vaccines currently known.
Compared with other vaccines, the 50% effective rate is about the average effective rate of influenza vaccine.
However, due to the large number of influenza viruses, multiple vaccines against different strains are needed, and the overall effectiveness is not high.
The picture shows the Institute of Butantin, Brazil on January 12th.
Researchers are reviewing the Kexing vaccine in production.
(Reuters)
New crown pneumonia | Brazil said that the effective rate of Kexing vaccine is only over 50%, and it is decided on Sunday whether to use
New crown pneumonia | Brazil will soon announce the results of Coxing's vaccine test, the media says the effective rate is less than 60%
The effective rate of Coxing vaccine test in Brazil is only 50% Nie Dequan: Expert Committee meets to review
The alleged effective rate is only over 50% of the Kexing vaccine Brazil report has repeatedly delayed the death of people who misrepresented vaccination
Some experts criticized that the figures released by the Butantan Institute were confusing, and Denise Garrett, an epidemiologist at the Sabin Vaccine Institute in the United States, criticized that the Brazilian authorities appeared to be because the vaccine data was not ideal. Postpone the announcement and look for ways to announce the figures in a more respectful way.
The data of Kexing Vaccine is not as good as ideal, which has dealt a blow to the local fight against the epidemic in Brazil. Especially after the Butantan Institute announced an earlier 78% efficiency, the authorities decided to purchase 10 million doses of Kexing vaccine.
Some local university experts pointed out that the Butantan Institute will face accusations from various sources in Brazil.
↓If you want to know the lives of people in other countries during the epidemic, please click to enlarge to watch:
01News
Covid-19 vaccine Covid-19 Brazil
